Ovarian Clear Cell Carcinoma Clinical Trial
Official title:
Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100
To learn if the combination of dostarlimab and LB-100 can help to control ovarian clear cell carcinoma
Primary Objectives: 1. To estimate overall survival in patients with recurrent ovarian clear cell carcinoma being treated with LB-100 and dostarlimab, including specific survival probabilities at 6 and 12 months. Secondary Objectives: 1. To describe clinically significant and immune related adverse events (ir-AEs) in the study population. 2. To determine the objective response rate (ORR), time to initial response, progression free survival (PFS), and duration of response (DOR) using modified RECIST v1.1 criteria. a. Although the clinical benefit of these drugs has not yet been established, the intent of offering this treatment is to provide a possible therapeutic benefit, and thus the patient will be carefully monitored for tumor response and symptom relief in addition to safety and tolerability. 3. Translational: 1. To describe PP2A activity and immune changes, using baseline and on-treatment tumor biopsies and peripheral blood mononuclear cells (PBMCs) 2. To describe expression of mismatch repair proteins using immunohistochemistry (IHC) 3. To correlate circulating tumor DNA (ctDNA) levels with response by modified RECIST v1.1 criteria. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
| Recruiting |
NCT05296512 -
Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT01914510 -
A Study of ENMD-2076 in Ovarian Clear Cell Cancers
|
Phase 2 | |
| Recruiting |
NCT04104776 -
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
|
Phase 1/Phase 2 | |
| Completed |
NCT03297424 -
A Study of PLX2853 in Advanced Malignancies.
|
Phase 1 | |
| Recruiting |
NCT03405454 -
A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas
|
Phase 2 | |
| Not yet recruiting |
NCT05600998 -
A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell Carcinoma
|
N/A | |
| Recruiting |
NCT05099978 -
Asian Multicenter Prospective Study of ctDNA Sequencing
|
||
| Not yet recruiting |
NCT05759312 -
Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell Carcinoma
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06279104 -
A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary
|
||
| Terminated |
NCT02837991 -
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
|
Phase 1 | |
| Recruiting |
NCT05498597 -
AMT-151 in Patients With Selected Advanced Solid Tumours
|
Phase 1 | |
| Recruiting |
NCT05226507 -
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
|
Phase 1 | |
| Recruiting |
NCT05281471 -
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
|
Phase 3 | |
| Recruiting |
NCT04735861 -
Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT02866370 -
Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium
|
Phase 2 |